Physician profile
Melissa Ott
NPI 1225166242
$12,939.90
in general payments reported to CMS, 2019-2025
35 companies · $2,496 in 2025
The $2,496 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,939 · 2022: $2,223 · 2023: $2,940 · 2024: $3,343 · 2025: $2,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,525 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,524.97 |
| Education | $253.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,016.98 | 2021-2025 | |
| Amgen INC. | $1,932.33 | 2021-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $1,510.65 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $995.14 | 2021-2025 | |
| Lilly USA, LLC | $977.72 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Astrazeneca Pharmaceuticals LP | $883.65 | 2021-2025 | Saphnelo |
| Ucb, INC. | $643.71 | 2021-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $564.18 | 2021-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $556.44 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $528.76 | 2022-2025 | |
| Organon LLC | $415.73 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Horizon Therapeutics Plc | $396.58 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $215.35 | 2022-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.32 | 2021-2024 | Ofev, Cyltezo |
| Fresenius Kabi USA, LLC | $172.45 | 2023-2025 | Idacio, Tyenne |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $134.90 | 2021-2025 | Actemra |
| Boston Scientific Corporation | $97.11 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Genzyme Corporation | $90.52 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $68.43 | 2023-2024 | Lupkynis |
| Radius Health, INC. | $65.80 | 2025 | |
| Tersera Therapeutics LLC | $53.52 | 2022-2025 | Quzyttir |
| Actelion Pharmaceuticals US, INC. | $51.52 | 2023-2025 | Uptravi, Opsynvi, Opsumit |
| Sandoz INC. | $50.62 | 2023-2024 | Hyrimoz |
| Mylan Institutional INC. | $46.00 | 2023 | Hulio |
| Hikma Pharmaceuticals USA | $40.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $35.77 | 2022-2023 | Seglentis |
| Alexion Pharmaceuticals, INC. | $32.84 | 2021 | |
| Sobi, INC | $28.94 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.27 | 2024 | |
| Octapharma USA, INC. | $23.39 | 2025 | Octagam Immune Globulin (Human) |
| Fidia Pharma USA INC. | $15.88 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.05 | 2021 | |
| Merck Sharp & Dohme LLC | $14.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Ferring Pharmaceuticals INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.